Myeloid Neoplasms appearing after Cytotoxic Therapy in Patients with Nasopharyngeal Carcinoma: Experience at a Single Institute

Author:

Huang Shih-Yun1,Wu Cheng-Han1,Jiang Rong-San1,Liu Yi-Chun1,Wang Chen-Chi1,Liang Kai-Li1

Affiliation:

1. Taichung Veterans General Hospital

Abstract

Abstract Objectives Myeloid neoplasms post cytotoxic therapy (MN-pCT) is a specific hematological disease arising after chemoradiotherapy (CRT) for a variety of primary unrelated malignancies or autoimmune diseases. MN-pCT after treatment of nasopharyngeal carcinoma (NPC) is rarely reported. Here, we aimed to determine the prevalence and risks of MN-pCT among individuals who have previously undergone treatment for NPC. Methods Data were retrieved from the cancer registry database of the study hospital. History of NPC patients who had undergone CRT during the period of 2006 to 2021 was reviewed. MN-pCT after NPC treatment were identified among them. In addition, a group of patients with de novo myeloid neoplasms matched with the gender and age of MN-pCT subjects were collected for comparison. Results A total of 9 patients with MN-pCT related to NPC therapy were identified. Six were myelodysplastic syndrome-post cytotoxic therapy (MDS-pCT) and 3 were acute myeloid leukemia-post cytotoxic therapy (AML-pCT). All had undergone high-dose radiotherapy and alkylating agents. The median time from NPC therapy to the diagnosis of MN-pCT was 7 years. MN-pCT patients presented with anemia, neutropenia, recurrent infection, and fatigue. All NPC related MN-pCT died when this study ended with a median overall survival of only 2 months. There were significant differences in survival between patients with MN-pCT and patients with de novo AML / MDS (P = 0.0001). Conclusion Individuals who have undergone intensive treatment for NPC display a propensity to develop MN-pCT. Despite the relatively low incidence of MN-pCT, the associated prognosis was dismal. This study emphasizes the importance of heightened vigilance when managing NPC survivors who have received intensive treatment even beyond the conventional 5-year surveillance period.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3